By Christopher Morrison and Roger Longman
Pfizer Inc.'s decision to discontinue the development of it's Phase III high-density lipoprotein-boosting torcetrapib in early December leaves the Big...
Pfizer's decision to discontinue the development of it's Phase III high-density lipoprotein-boosting torcetrapib in early December leaves the Big Pharma with little choice but to accelerate its restructuring plans and start spending some of its estimated $34 billion cash reserves to bolster its pipeline.
By Christopher Morrison and Roger Longman
Pfizer Inc.'s decision to discontinue the development of it's Phase III high-density lipoprotein-boosting torcetrapib in early December leaves the Big...
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.